4/A: Rockwell Medical SVP and CCO Amends Filing for Stock Sale Under 10b5-1 Plan

Timothy Chole, SVP and CCO of Rockwell Medical, Inc., amended a Form 4 filing to clarify that his sale of 2,868 shares of common stock on July 1, 2025, was executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Timothy Chole, SVP and CCO of Rockwell Medical, Inc. (RMTI), filed an amendment to his Form 4.
• The amendment clarifies that a transaction involving the sale of 2,868 shares of RMTI common stock was made pursuant to a Rule 10b5-1 trading plan.
• The transaction occurred on July 1, 2025, at a weighted average sales price of $0.82 per share, with prices ranging from $0.80 to $0.83.
• Following this transaction, Timothy Chole beneficially owns 128,167 shares of common stock.
• The Rule 10b5-1 trading plan was adopted on June 7, 2024.

Sentiment

Score: 5

Explanation: This is a routine insider transaction filing. The sale is pre-planned via a 10b5-1 plan, which reduces the negative signal often associated with insider selling. The amendment is administrative.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to immediate market conditions, which enhances transparency.

Negatives

• An insider, Timothy Chole, sold 2,868 shares of common stock.

Future Outlook

No future outlook or guidance is provided in this Form 4/A filing, as it primarily reports an insider transaction.

Management Comments

• "This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024 in multiple trades at prices ranging from $0.80 to $0.83. The price reported above reflects the weighted average sales price."
• "The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."

Industry Context

This Form 4/A is a routine disclosure of an insider stock transaction and does not provide specific industry context or trends. It reflects an individual officer's pre-planned stock sale.

Stakeholder Impact

• Shareholders: May observe a slight increase in shares available on the market due to the sale, but the impact is minimal given the small number of shares. The 10b5-1 plan provides transparency regarding the pre-planned nature of the transaction.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares and prices upon request to the SEC staff, the Issuer, or a security holder.

Key Dates

Keywords

Rockwell Medical, RMTI, Timothy Chole, Form 4, SEC filing, insider trading, stock sale, 10b5-1 plan, corporate officer, common stock